The Reflux Disease Questionnaire: a measure for assessment of treatment response in clinical trials
<p>Abstract</p> <p>Background</p> <p>Critical needs for treatment trials in gastroesophageal reflux disease (GERD) include assessing response to treatment, evaluating symptom severity, and translation of symptom questionnaires into multiple languages. We evaluated the p...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2008-04-01
|
| Series: | Health and Quality of Life Outcomes |
| Online Access: | http://www.hqlo.com/content/6/1/31 |
| _version_ | 1818960698945830912 |
|---|---|
| author | Junghard Ola Beebe Timothy Dent John Shaw Michael Wiklund Ingela Lind Tore Johnsson Folke |
| author_facet | Junghard Ola Beebe Timothy Dent John Shaw Michael Wiklund Ingela Lind Tore Johnsson Folke |
| author_sort | Junghard Ola |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Critical needs for treatment trials in gastroesophageal reflux disease (GERD) include assessing response to treatment, evaluating symptom severity, and translation of symptom questionnaires into multiple languages. We evaluated the previously validated Reflux Disease Questionnaire (RDQ) for internal consistency, reliability, responsiveness to change during treatment and the concordance between RDQ and specialty physician assessment of symptom severity, after translation into Swedish and Norwegian.</p> <p>Methods</p> <p>Performance of the RDQ after translation into Swedish and Norwegian was evaluated in 439 patients with presumed GERD in a randomized, double-blind trial of active treatment with a proton pump inhibitor.</p> <p>Results</p> <p>The responsiveness was excellent across three RDQ indicators. Mean change scores in patients on active treatment were large, also reflected in effect sizes that ranged from a low of 1.05 (dyspepsia) to a high of 2.05 (heartburn) and standardized response means 0.99 (dyspepsia) and 1.52 (heartburn). A good positive correlation between physician severity ratings and RDQ scale scores was seen. The internal consistency reliability using alpha coefficients of the scales, regardless of language, ranged from 0.67 to 0.89.</p> <p>Conclusion</p> <p>The results provide strong evidence that the RDQ is amenable to translation and represents a viable instrument for assessing response to treatment, and symptom severity.</p> |
| first_indexed | 2024-12-20T12:01:41Z |
| format | Article |
| id | doaj.art-a21506d4758941639bdb3a6174d58142 |
| institution | Directory Open Access Journal |
| issn | 1477-7525 |
| language | English |
| last_indexed | 2024-12-20T12:01:41Z |
| publishDate | 2008-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Health and Quality of Life Outcomes |
| spelling | doaj.art-a21506d4758941639bdb3a6174d581422022-12-21T19:41:31ZengBMCHealth and Quality of Life Outcomes1477-75252008-04-01613110.1186/1477-7525-6-31The Reflux Disease Questionnaire: a measure for assessment of treatment response in clinical trialsJunghard OlaBeebe TimothyDent JohnShaw MichaelWiklund IngelaLind ToreJohnsson Folke<p>Abstract</p> <p>Background</p> <p>Critical needs for treatment trials in gastroesophageal reflux disease (GERD) include assessing response to treatment, evaluating symptom severity, and translation of symptom questionnaires into multiple languages. We evaluated the previously validated Reflux Disease Questionnaire (RDQ) for internal consistency, reliability, responsiveness to change during treatment and the concordance between RDQ and specialty physician assessment of symptom severity, after translation into Swedish and Norwegian.</p> <p>Methods</p> <p>Performance of the RDQ after translation into Swedish and Norwegian was evaluated in 439 patients with presumed GERD in a randomized, double-blind trial of active treatment with a proton pump inhibitor.</p> <p>Results</p> <p>The responsiveness was excellent across three RDQ indicators. Mean change scores in patients on active treatment were large, also reflected in effect sizes that ranged from a low of 1.05 (dyspepsia) to a high of 2.05 (heartburn) and standardized response means 0.99 (dyspepsia) and 1.52 (heartburn). A good positive correlation between physician severity ratings and RDQ scale scores was seen. The internal consistency reliability using alpha coefficients of the scales, regardless of language, ranged from 0.67 to 0.89.</p> <p>Conclusion</p> <p>The results provide strong evidence that the RDQ is amenable to translation and represents a viable instrument for assessing response to treatment, and symptom severity.</p>http://www.hqlo.com/content/6/1/31 |
| spellingShingle | Junghard Ola Beebe Timothy Dent John Shaw Michael Wiklund Ingela Lind Tore Johnsson Folke The Reflux Disease Questionnaire: a measure for assessment of treatment response in clinical trials Health and Quality of Life Outcomes |
| title | The Reflux Disease Questionnaire: a measure for assessment of treatment response in clinical trials |
| title_full | The Reflux Disease Questionnaire: a measure for assessment of treatment response in clinical trials |
| title_fullStr | The Reflux Disease Questionnaire: a measure for assessment of treatment response in clinical trials |
| title_full_unstemmed | The Reflux Disease Questionnaire: a measure for assessment of treatment response in clinical trials |
| title_short | The Reflux Disease Questionnaire: a measure for assessment of treatment response in clinical trials |
| title_sort | reflux disease questionnaire a measure for assessment of treatment response in clinical trials |
| url | http://www.hqlo.com/content/6/1/31 |
| work_keys_str_mv | AT junghardola therefluxdiseasequestionnaireameasureforassessmentoftreatmentresponseinclinicaltrials AT beebetimothy therefluxdiseasequestionnaireameasureforassessmentoftreatmentresponseinclinicaltrials AT dentjohn therefluxdiseasequestionnaireameasureforassessmentoftreatmentresponseinclinicaltrials AT shawmichael therefluxdiseasequestionnaireameasureforassessmentoftreatmentresponseinclinicaltrials AT wiklundingela therefluxdiseasequestionnaireameasureforassessmentoftreatmentresponseinclinicaltrials AT lindtore therefluxdiseasequestionnaireameasureforassessmentoftreatmentresponseinclinicaltrials AT johnssonfolke therefluxdiseasequestionnaireameasureforassessmentoftreatmentresponseinclinicaltrials AT junghardola refluxdiseasequestionnaireameasureforassessmentoftreatmentresponseinclinicaltrials AT beebetimothy refluxdiseasequestionnaireameasureforassessmentoftreatmentresponseinclinicaltrials AT dentjohn refluxdiseasequestionnaireameasureforassessmentoftreatmentresponseinclinicaltrials AT shawmichael refluxdiseasequestionnaireameasureforassessmentoftreatmentresponseinclinicaltrials AT wiklundingela refluxdiseasequestionnaireameasureforassessmentoftreatmentresponseinclinicaltrials AT lindtore refluxdiseasequestionnaireameasureforassessmentoftreatmentresponseinclinicaltrials AT johnssonfolke refluxdiseasequestionnaireameasureforassessmentoftreatmentresponseinclinicaltrials |